A woman who was told she had a terminal brain tumor and underwent 11 years of chemotherapy has discovered she never had cancer. Becky Jones, then 21, was diagnosed with an aggressive brain tumor and given only months to live. Instead of pursuing her dream career in the police, she spent the next decade undergoing chemotherapy, enduring debilitating side effects and the constant fear of death.
Independent experts later concluded that Jones was suffering from tumefactive demyelination, an inflammatory condition of the brain that can be mistaken for a tumor on scans and is treatable with steroids.
Jones' case has emerged as part of a wider scandal at University Hospitals Coventry and Warwickshire NHS Trust, involving patients treated under retired consultant neuro-oncologist Professor Ian Brown. More than 40 patients and families are pursuing legal action over allegations of prolonged or unnecessary cancer treatment.
A review by the Royal College of Physicians examined 20 cases and found significant failures in clinical decision-making, patient consent, and oversight. None of the reviewed cases demonstrated good practice, with 15 deemed unsatisfactory. The review highlighted repeated instances of chemotherapy, including over 100 cycles of temozolomide in some cases, being administered for years without clear justification or adequate documentation.
Patients were reportedly not adequately warned about the risks of prolonged treatment, and systems designed to challenge unusual prescribing practices appeared to have failed. The review suggested that Professor Brown's conduct be referred to the General Medical Council.
Jones' ordeal began in 2012 with severe migraines, leading to scans that revealed a lesion on her brain. After a biopsy, she was treated for glioblastoma, a high-grade brain cancer, despite her lawyers stating the diagnosis was made before biopsy results returned. She was told she had six to 12 months to live without treatment and was placed on temozolomide, a chemotherapy drug.
Despite national guidance typically recommending a limited course of temozolomide for high-grade brain tumors, Jones was informed she needed indefinite treatment. She continued receiving the drug for over a decade, experiencing nausea, fatigue, and isolation, and was warned she might never have children, though she went on to have two.
Her chemotherapy was finally halted in 2024 when a doctor informed her of the discontinuation following Professor Brown's retirement, with little initial explanation regarding her ongoing care.
In 2025, independent medical experts reviewed her case and determined the lesion was not cancerous but likely tumefactive demyelination. The revelation came as a shock, leaving Jones to grapple with the impact of years of treatment for a condition she never had.
The Royal College of Physicians' review focused on patients who received more than 12 cycles of temozolomide at the trust between 2017 and 2023. It identified prolonged chemotherapy without clear evidence of benefit, poor record-keeping, and a lack of adherence to clinical guidelines. The review also questioned why hospital teams did not challenge cases of continuous oral chemotherapy lasting 10 to 15 years, citing a 'bystander effect' where responsibility for challenging unusual practices was passed between individuals and departments.
Lawyers representing affected patients believe the 20 cases reviewed are likely a fraction of those impacted. The review recommended that living patients who received extended temozolomide beyond 12 cycles should be assessed, and consideration should be given to patients who have since died.
The University Hospitals Coventry and Warwickshire NHS Trust stated that affected patients have been reviewed by senior clinicians and appropriate care plans implemented. The trust has also commissioned an independent examination of its internal processes for staff to raise concerns, emphasizing that patient safety remains its priority.